Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltanexor (ATG-016) Ib/II in advanced solid tumors
CTR20211496Phase 2Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltanexor in Nonhematologic neoplasms, penile squamous cell carcinoma (PSCC), nasopharyngeal carcinoma (NPC), sponsored by Karyopharm Therapeutics Inc.. Started Aug 2021; status: terminated.
02
Drugs
eltanexor
03
Conditions
Nonhematologic neoplasmspenile squamous cell carcinoma (PSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20211496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211496.